Cell Death Signaling in Cancer Biology and Treatment

2013
ISBN: 978-1-4939-0107-4
Verlag: Springer US

Buch, Englisch, 408 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 639 g

Reihe: Cell Death in Biology and Diseases

A key goal in the treatment of cancer is to achieve selective and efficient killing of tumor cells. The aim of Cell Death Signaling in Cancer Biology and Treatment is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell death due to overexpression/hyperactivation of oncoproteins, as well as the loss of tumor suppressor proteins will be described. The potential for targeting microRNAs will be discussed. Multiple chapters will describe preclinical and clinical approaches that are currently being used to target epigenetic modifications, DNA repair pathways, and protein chaperones, as a means of provoking tumor cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Johnson, Daniel

Fachgebiete

• Naturwissenschaften Biowissenschaften Zellbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie

Inhaltsverzeichnis

Defective Apoptosis Signaling in Cancer.- The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells.- Emerging Opportunities for Targeting the Tumor-Stroma Interactions for Increasing the Efficacy of Chemotherapy.- The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting.- microRNAs in Cell Death and Cancer.- Targeting DNA Repair Pathways for Cancer Therapy.- Molecular Chaperones and How Addiction Matters in Cancer Therapy.- Sphingolipid Metabolism and Signaling as a Target for Cancer Treatment.- Leading Small Molecule Inhibitors of Anti-apoptotic Bcl-2 Family Members.- SMAC IAP Addiction in Cancer.- Harnessing Death Receptor Signaling for Cancer Treatment.- Proteasome Inhibition as a Novel Strategy for Cancer Treatment.- New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways.- Activation of Immune-Mediated Tumor Cell Death by Chemotherapy.

Über Autor(innen)

Dr. Daniel E. Johnson received his undergraduate training at North Park University and his doctoral degree in molecular biology from Princeton University.  He was a postdoctoral fellow at the University of California San Francisco.  In 1993 he joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute, where he is currently a Professor in the Departments of Medicine and Pharmacology & Chemical Biology.  Dr. Johnson has served as a standing member on study sections for the National Institutes of Health and American Cancer Society, and is a long-standing Section Editor for the journal Leukemia.  His research has focused on molecular mechanisms of apoptosis in leukemia and head and neck cancer, as well as the mechanisms of myeloid differentiation.  He has placed particular emphasis on the translation of findings from his laboratory to the clinic, and together with physician scientist collaborators has helped develop ongoing trials in both acute myeloid leukemia and head and neck cancer.